Combination therapy for relapsed B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of two treatments—blinatumomab and a special type of immune cell called iNKT—to fight B-cell acute lymphoblastic leukemia (ALL) that has returned or is not responding well after prior treatment. The goal is to see if this combination is safe and effective for patients who have had a relapse or new minimal residual disease (MRD) after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (ALL).
- Your leukemia shows signs of returning (either new MRD positivity after being MRD negative before, or a frank relapse) while receiving or after treatment with blinatumomab.
- You are able to understand and agree to the trial procedures and sign a consent form.
- You do not have CD19-negative leukemia, active central nervous system involvement, uncontrolled infection, or Philadelphia-positive disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This study tests two targeted drugs, inotuzumab and blinatumomab, for people with B-cell acute lymphoblastic leukemia (ALL). The goal is to see if this combination can help control the cancer and possibly be an option for those who cannot have standard chemotherapy.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
Hear when a new ALL (Acute B-Lymphoblastic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.